FDA OKs Lilly’s Cyramza as first-line treatment for lung cancer

The FDA has approved Eli Lilly’s (NYSE:LLY) CYRAMZA (ramucirumab injection, 10 mg/mL solution), in combination with erlotinib, for the first-line treatment of people with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations.

With this approval, CYRAMZA has now received six FDA approvals to treat certain types of lung, liver, stomach and colorectal cancers.

https://seekingalpha.com/news/3578886-fda-oks-lillys-cyramza-first-line-treatment-for-lung-cancer